The increasing availability of public data sets, such as The Cancer Genome Atlas (TCGA) and the Alzheimer s Disease Neuroimaging Initiative (ADNI), offers a transformational opportunity for insight-driven planning at all phases of the drug development life cycle. The size and scope of these publOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.